kras mutation and glutathion JCI Overcoming resistance to drugs targeting
Overcoming resistance to drugs targeting KRASG12C mutation The roles of KRAS in cancer metabolism, tumor microenvironment and clinical therapy PMC Metabolic networks in mutant KRAS driven tumours: tissue specificities and the microenvironment Nature Reviews Cancer KRAS targeted therapies in cancer: novel approaches and overcoming resistance BMJ Oncology Targeting KRAS Mutant Cancers with a Covalent G12C Specific Inhibitor: Cell
Pay in 4 interest-free payments of $7.10 Learn more
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours · Estimated delivery Aug 3 - Aug 8




